Select Publications

Journal articles

Copland E; Canoy D; Nazarzadeh M; Bidel Z; Ramakrishnan R; Woodward M; Chalmers J; Teo KK; Pepine CJ; Davis BR; Kjeldsen S; Sundström J; Rahimi K; Adler A; Agodoa L; Algra A; Asselbergs FW; Beckett N; Berge E; Black H; Brouwers FPJ; Brown M; Bulpitt CJ; Byington B; Chalmers J; Cushman WC; Cutler J; Davis BR; Devereaux RB; Dwyer J; Estacio R; Fagard R; Fox K; Fukui T; Gupta AK; Holman RR; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis J; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer C; Patel A; Pepine CJ; Pfeffer M; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Woodward M; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Pitt B; Rodgers A; Rothwell P; Salimi-Khorshidi G, 2021, 'Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis', The Lancet Oncology, vol. 22, pp. 558 - 570, http://dx.doi.org/10.1016/S1470-2045(21)00033-4

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program', ESC Heart Failure, vol. 8, pp. 1482 - 1493, http://dx.doi.org/10.1002/ehf2.13236

Oshima M; Jardine MJ; Agarwal R; Bakris G; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Lim SK; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V; Heerspink HJL, 2021, 'Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice', Kidney International, vol. 99, pp. 999 - 1009, http://dx.doi.org/10.1016/j.kint.2020.10.042

Sarraju A; Li JW; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW, 2021, 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial', American Heart Journal, vol. 233, pp. 141 - 148, http://dx.doi.org/10.1016/j.ahj.2020.12.008

Htay H; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Gharbi MB; Davison SN; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx VA; Neuen B; O'Donoghue D; Ossareh S; Perl J; Rashid HU; Rondeau E; See EJ; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Yee-Moon Wang A; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey FJ; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Harris DC; Johnson DW, 2021, 'Hemodialysis Use and Practice Patterns: An International Survey Study', American Journal of Kidney Diseases, vol. 77, pp. 326 - 335.e1, http://dx.doi.org/10.1053/j.ajkd.2020.05.030

O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V, 2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, vol. 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281

Evans RDR; Smyth B; Levin A; Jha V; Wheeler DC; Jardine M; Perkovic V; Damster S; Malik C; de Zeeuw D; Hiemstra T, 2021, 'The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals', Kidney International, vol. 99, pp. 551 - 554, http://dx.doi.org/10.1016/j.kint.2020.10.048

Yu J; Zhou Z; Mahaffey KW; Matthews DR; Neuen BL; Heerspink HJL; Jardine MJ; Li JW; Perkovic V; Neal B; Arnott C, 2021, 'An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials', International Journal of Cardiology, vol. 324, pp. 165 - 172, http://dx.doi.org/10.1016/j.ijcard.2020.09.050

Oshima M; Hara A; Toyama T; Jun M; Pollock C; Jardine M; Harrap S; Poulter N; Cooper ME; Woodward M; Chalmers J; Perkovic V; Wong MG; Wada T, 2021, 'Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor', Kidney International Reports, vol. 6, pp. 284 - 295, http://dx.doi.org/10.1016/j.ekir.2020.10.039

Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL, 2021, 'Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial', Diabetes, Obesity and Metabolism, vol. 23, pp. 561 - 568, http://dx.doi.org/10.1111/dom.14252

Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL, 2021, 'Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes', Diabetes, Obesity and Metabolism, vol. 23, pp. 382 - 390, http://dx.doi.org/10.1111/dom.14226

Wang KM; Li JW; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI, 2021, 'Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program', Endocrinology, Diabetes and Metabolism, http://dx.doi.org/10.1002/edm2.247

Perkovic V; Koitka-Weber A; Cooper ME; Schernthaner G; Pfarr E; Woerle HJ; von Eynatten M; Wanner C, 2021, 'Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOMEVR trial', Nephrology Dialysis Transplantation, vol. 35, pp. 2103 - 2111, http://dx.doi.org/10.1093/NDT/GFZ179

Kotwal S; Perkovic V, 2021, 'Forever starts now: Effects of glucose-lowering therapies on acute kidney injury', Clinical Journal of the American Society of Nephrology, vol. 16, pp. 6 - 8, http://dx.doi.org/10.2215/CJN.18141120

Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2021, 'Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis', Clinical Journal of the American Society of Nephrology, vol. 16, pp. 384 - 395, http://dx.doi.org/10.2215/CJN.15260920

Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC, 2021, 'Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program', American Journal of Kidney Diseases, vol. 77, pp. 23 - 34.e1, http://dx.doi.org/10.1053/j.ajkd.2020.06.018

Li C; Zhou Z; Neuen BL; Yu J; Huang Y; Young T; Li J; Li L; Perkovic V; Jardine MJ; Keay L; Markoulli M; Rosenthal N; Capuano G; Yavin Y; Neal B; Arnott C, 2021, 'Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, vol. 23, pp. 252 - 257, http://dx.doi.org/10.1111/dom.14197

Neuen BL; Jardine MJ; Perkovic V, 2021, 'Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?', Nephrology Dialysis Transplantation, vol. 35, pp. I48 - I55, http://dx.doi.org/10.1093/NDT/GFZ252

Jun M; Harris K; Heerspink HJL; Badve SV; Jardine MJ; Harrap S; Hamet P; Marre M; Poulter N; Kotwal S; Gallagher M; Perkovic V; Chalmers J; Woodward M, 2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, http://dx.doi.org/10.1111/dom.14351

Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V, 2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, vol. 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620

Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX, 2020, 'Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD', Clinical Journal of the American Society of Nephrology, vol. 15, pp. 1728 - 1739, http://dx.doi.org/10.2215/CJN.08310520

Oshima M; Neuen BL; Li JW; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; de Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial', Journal of the American Society of Nephrology, vol. 31, pp. 2925 - 2936, http://dx.doi.org/10.1681/ASN.2020050723

Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM; Wyndham R; Vilayur E; Cooper B; Wong MG; Tan KS; van Eps C; Cho Y; Barbara J; Paizis K; McMahon LP; Nelson C; Gafor AHA; Meng OL; Mushahar L; Maher E, 2020, 'A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)', Journal of the American Society of Nephrology, vol. 31, pp. 2653 - 2666, http://dx.doi.org/10.1681/ASN.2020040411

Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL, 2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, vol. 8, pp. 903 - 914, http://dx.doi.org/10.1016/S2213-8587(20)30300-4

Matthews DR; Wysham C; Davies M; Slee A; Alba M; Lee M; Perkovic V; Mahaffey KW; Neal B, 2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, vol. 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; de Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning', Journal of Cardiac Failure, vol. 26, pp. 1028 - 1029, http://dx.doi.org/10.1016/j.cardfail.2020.09.001

Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B, 2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, vol. 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011

Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V, 2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, vol. 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312

Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C, 2020, 'Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: Post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial', Clinical Journal of the American Society of Nephrology, vol. 15, pp. 1433 - 1444, http://dx.doi.org/10.2215/CJN.14901219

Levin A; Agarwal R; Herrington WG; Heerspink HL; Mann JFE; Shahinfar S; Tuttle KR; Donner JA; Jha V; Nangaku M; de Zeeuw D; Jardine MJ; Mahaffey KW; Thompson AM; Beaucage M; Chong K; Roberts GV; Sunwold D; Vorster H; Warren M; Damster S; Malik C; Perkovic V; Anand S; Argent N; Babak E; Banerjee D; Barratt J; Bello AK; Bernardo AA; Blais J; Canovatchel W; Caskey FJ; Coresh J; de Boer IH; Eckardt KU; Evans RD; Feldman HI; Fogo AB; Gudmundsdottir H; Hamano T; Harris DCH; Hauske SJ; Haynes R; Herzog CA; Hiemstra T; Idorn T; Inker L; Ishida JH; Johnson DW; Jones-Burton C; Joseph A; Koitka-Weber A; Kretzler M; Lawatscheck R; Liew A; Moist L; Naicker S; Nakashima R; Patel U; Filho RP; Rose JB; Rosenberg NL; Sinsakul M; Smoyer WE; Sola L; Sood AR; Stengel B; Taal MW; Tanaka M; Tonelli M; Tong A; Toto R; Trask M; Ulasi II; Wanner C; Wheeler DC; Wolthers BO; Wright HM; Yamada Y; Zakharova E, 2020, 'International consensus definitions of clinical trial outcomes for kidney failure: 2020', Kidney International, vol. 98, pp. 849 - 859, http://dx.doi.org/10.1016/j.kint.2020.07.013

Smyth B; Zuo L; Gray NA; Chan CT; de Zoysa JR; Hong D; Rogers K; Wang J; Cass A; Gallagher M; Perkovic V; Jardine M, 2020, 'No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial', Nephrology, vol. 25, pp. 792 - 800, http://dx.doi.org/10.1111/nep.13737

Torda AJ; Velan G; Perkovic V, 2020, 'The impact of the COVID-19 pandemic on medical education', Medical Journal of Australia, vol. 213, pp. 334 - 334.e1, http://dx.doi.org/10.5694/mja2.50762

Zhu B; Jun M; Jardine MJ; Wang YJ; Perkovic V, 2020, 'Haemodialysis duration, frequency and intensity for end-stage kidney disease', Cochrane Database of Systematic Reviews, vol. 2020, http://dx.doi.org/10.1002/14651858.CD010064.pub2

Li JW; Neal B; Perkovic V; de Zeeuw D; Neuen BL; Arnott C; Simpson R; Oh R; Mahaffey KW; Heerspink HJL, 2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, vol. 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051

Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M, 2020, 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials', Clinical Journal of the American Society of Nephrology, vol. 15, pp. 1129 - 1138, http://dx.doi.org/10.2215/CJN.12201019

Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; Eynatten MV; George JT; Johansen OE; Wanner C, 2020, 'Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the carmelina randomized trial', Diabetes Care, vol. 43, pp. 1803 - 1812, http://dx.doi.org/10.2337/dc20-0279

Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; De Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW, 2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, vol. 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/NEJMoa1915833

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; De Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, vol. 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010

Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B, 2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, http://dx.doi.org/10.1111/dom.14091

Torda A; Perkovic V; Velan G, 2020, 'The impact of COVID-19 pandemic on medical education', Medical Journal of Australia, https://www.mja.com.au/journal/2020/impact-covid-19-pandemic-medical-education

Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V, 2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, vol. 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168

Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B, 2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, vol. 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920

Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M, 2020, 'Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial', Diabetology International, vol. 11, pp. 129 - 141, http://dx.doi.org/10.1007/s13340-019-00412-x

Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B, 2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, vol. 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908

Cannon CP; Perkovic V; Agarwal R; Baldassarre J; Bakris G; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Jardine MJ; Levin A; Li JW; Neal B; Pollock C; Wheeler DC; Zhang H; Zinman B; Mahaffey KW, 2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, including Those with HbA1c <7%: Results from the CREDENCE Trial', Circulation, vol. 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359

Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan DE; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL, 2020, 'Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease', Clinical Pharmacology and Therapeutics, http://dx.doi.org/10.1002/cpt.2143

Li JW; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B, 2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, vol. 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004

Neuen BL; Perkovic V, 2020, 'Pilot trials in nephrology: Establishing a base for large-scale randomized trials', Journal of the American Society of Nephrology, vol. 31, pp. 4 - 6, http://dx.doi.org/10.1681/ASN.2019111196

Smyth B; van den Broek-Best O; Hong D; Howard K; Rogers K; Zuo L; Gray NA; de Zoysa JR; Chan CT; Lin H; Zhang L; Xu J; Cass A; Gallagher M; Perkovic V; Jardine M, 2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, vol. 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619

Li JW; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, vol. 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5


Back to profile page